Ambu A/ S stock (DK0060946788): focus on endoscopy demand after latest quarterly report

Ambu A/S recently reported quarterly results and updated investors on demand trends for its single-use endoscopy portfolio, giving the market fresh data on growth, profitability and hospital spending patterns relevant for global and US-focused healthcare investors.

Ambu A/S, a Danish medtech company best known for its single-use endoscopes and anesthesia products, recently presented financial results for its second quarter of fiscal year 2024/25 and commented on demand trends in endoscopy and patient monitoring, giving investors an updated view on revenue growth, profitability and hospital capital spending, according to a company release published on 05/07/2025 on its investor website (Ambu investor update as of 05/07/2025) and follow-up coverage by financial media on the same day (Reuters as of 05/07/2025).

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Ambu
• Sector/industry: Medical technology / single-use endoscopy and patient monitoring
• Headquarters/country: Denmark
• Core markets: Hospitals and clinics in Europe, North America and selected international markets
• Key revenue drivers: Single-use endoscopes, anesthesia and patient monitoring devices
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: AMBU-B)
• Trading currency: Danish krone (DKK)

Ambu A/S: core business model

Ambu A/S operates as a specialized medical technology company focused on devices for hospitals and clinics, with a notable emphasis on single-use medical devices. The group’s activities center on designing, manufacturing and marketing products used in airway management, anesthesia and endoscopy. Management highlights that its single-use portfolio aims to address infection control, workflow efficiency and capacity challenges in modern hospital environments, according to its latest annual report for fiscal 2023/24 released on 11/19/2024 (Ambu annual report as of 11/19/2024).

In recent years Ambu has increasingly positioned itself as a leader in single-use endoscopy, a technology that replaces reusable scopes and the associated cleaning infrastructure with disposable devices. This strategy seeks to respond to hospital concerns about cross-contamination and the logistics of reprocessing reusable equipment. The company’s endoscopy systems combine single-use scopes with visualization platforms, which are typically installed in procedure rooms, according to company product descriptions updated in 2024 (Ambu product information as of 09/10/2024).

Besides endoscopy, Ambu generates revenue from airway management and anesthesia products such as laryngeal masks, resuscitators and related consumables. These devices are used across emergency departments, operating rooms and intensive care units. The business model relies heavily on recurring sales of disposable components, which can create a more predictable revenue stream once hospitals adopt the company’s systems. This consumables-driven approach is a common feature among medtech companies targeting procedure volumes rather than one-off capital equipment sales.

Ambu sells its products primarily through its own sales organizations in key markets and via distributors in other geographies. North America, including the United States, has become one of its most important regions, especially for endoscopy adoption. The company notes that procurement decisions often involve hospital systems and group purchasing organizations, and it competes with both large diversified medtech players and specialized device makers. Revenue is reported in Danish kroner but reflects exposure to US dollar and euro movements, which can affect reported growth and margins when currencies fluctuate.

Main revenue and product drivers for Ambu A/S

Ambu’s main revenue driver in recent years has been its single-use endoscopy segment, which includes bronchoscopes, ENT scopes and solutions for gastroenterology and urology. Management reported that single-use endoscopy continued to deliver organic revenue growth in the mid- to high-single-digit range in the second quarter of fiscal 2024/25, supported by increased procedural volumes and new account wins, according to its Q2 2024/25 announcement on 05/07/2025 (Ambu Q2 2024/25 report as of 05/07/2025). The company has highlighted particularly strong interest in single-use bronchoscopes in intensive care and operating room settings.

Airway management and anesthesia products form the other major pillar of Ambu’s revenue mix. These product lines historically represented a significant portion of total sales and are used in both elective and emergency procedures. In its fiscal 2023/24 results, Ambu indicated that airway management delivered stable to slightly growing revenue, supported by continued demand in developed markets and selective product launches, while price competition and procurement dynamics remained a factor in some regions, according to its release on 11/19/2024 (Ambu FY 2023/24 results as of 11/19/2024).

Profitability is influenced by product mix between higher-margin endoscopy consumables and other product categories, as well as by manufacturing efficiency. Ambu has previously outlined initiatives to optimize its supply chain and production footprint, including automation and capacity adjustments, with the aim of improving gross margin over time. These efforts were referenced again during the Q2 2024/25 results communication, where management described progress on cost-saving programs and operational efficiencies that are expected to support earnings in the medium term, as noted in the accompanying presentation published on 05/07/2025 (Ambu Q2 2024/25 presentation as of 05/07/2025).

Beyond organic growth, Ambu’s revenue trajectory also depends on the pace of new product introductions and regulatory clearances. Single-use endoscopes and associated visualization platforms require regulatory approvals in various jurisdictions, including the US Food and Drug Administration for products marketed in the United States. The company has reported that it continues to work on expanding its portfolio and indications, adding incremental procedure types that can be addressed by single-use technologies, according to pipeline comments in its FY 2023/24 annual report released on 11/19/2024 (Ambu pipeline update as of 11/19/2024).

Another driver is hospital budgeting and the broader macroeconomic environment. Single-use endoscopes can shift spending from capital expenditure on reusable equipment and cleaning systems to operational expenditure on consumables. In its recent communications, Ambu noted that hospital decision processes remain cautious but that infection control, staffing constraints and operational flexibility continue to support interest in single-use solutions, particularly in markets with high focus on patient safety and throughput, according to management commentary in the Q2 2024/25 call transcript dated 05/07/2025 (Ambu Q2 2024/25 call as of 05/07/2025).

Conclusion

Ambu A/S offers investors exposure to structural themes in hospital care such as infection control, procedure efficiency and the shift toward single-use devices, with single-use endoscopy playing a central role in its growth story. Recent quarterly results for fiscal 2024/25 showed continued revenue expansion in endoscopy and ongoing efforts to improve profitability through operational initiatives and product mix, according to the company’s 05/07/2025 release. At the same time, the business remains sensitive to hospital budgeting cycles, competitive dynamics and regulatory milestones in key markets including the United States, where adoption trends are closely watched by global investors. For US-focused portfolios that track international medtech names, Ambu’s performance offers a lens on demand for single-use endoscopes and related consumables in both European and North American healthcare systems, but the usual uncertainties around reimbursement, pricing and macroeconomic conditions remain relevant considerations.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.